BioSante Pharmaceuticals to Host Conference Call to Announce LibiGel(R) Special Protocol Assessment (SPA).LINCOLNSHIRE, Ill. -- BioSante Pharmaceuticals, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : BPAX) today announced that it will host a conference call tomorrow, Tuesday, January 29, 2008 at 11:00 a.m. ET to announce and discuss the LibiGel (testosterone gel) SPA received from the U.S. Food and Drug Administration (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ) for the development of LibiGel in the treatment of female sexual dysfunction sexual dysfunction Inability to experience arousal or achieve sexual satisfaction under ordinary circumstances, as a result of psychological or physiological problems. . Details for the call are provided below. Conference Call Information When - Tuesday, January 29, 2008 at 11:00 a.m. ET Live Domestic and Canada call in: - 877-407-0778 Live international call in - 201-689-8565 Website for listen only http://www.vcall.com/IC/CEPage.asp?ID=125262 Replay Domestic and Canada - 877-660-6853 Replay International - 201-612-7415 24 hour replay, web access http://www.vcall.com/IC/CEPage.asp?ID=125262 Replay pass codes, (both required for playback) Account # - 286 Conference ID - 271970 About BioSante Pharmaceuticals, Inc. BioSante is developing a pipeline of hormone therapy Hormone therapy Treating cancers by changing the hormone balance of the body, instead of by using cell-killing drugs. Mentioned in: Breast Cancer, Thyroid Cancer hormone therapy products to treat both men and women. These hormone therapy products are gel formulations for transdermal administration that deliver bioidentical estradiol and testosterone. BioSante's lead products include LibiGel[R] (transdermal testosterone gel) in Phase III clinical development by BioSante for the treatment of female sexual dysfunction (FSD FSD Female Sexual Dysfunction FSD File System Driver FSD Family Support Division FSD Fire Services Department (Hong Kong) FSD Full Scale Development FSD Full Scale Deflection FSD Federal Systems Division ) and Elestrin[TM] (estradiol gel) developed through U.S. Food and Drug Administration (FDA) approval by BioSante indicated for the treatment of moderate-to-severe vasomotor vasomotor /vaso·mo·tor/ (-mo´tor) 1. affecting the caliber of blood vessels. 2. a vasomotor agent or nerve. va·so·mo·tor adj. symptoms associated with menopause, marketed in the U.S. by Bradley Pharmaceuticals, Inc., BioSante's licensee. Also in development are Bio-T-Gel[TM], a testosterone gel for male hypogonadism, and an oral contraceptive oral contraceptive n. A pill, typically containing estrogen or progesterone, that prevents conception or pregnancy. Also called birth control pill. in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3.0 billion. The company also is developing its calcium phosphate nanotechnology (CaP) for novel vaccines, drug delivery, and aesthetic medicine (BioLook[TM]). Additional information is available online at: www.biosantepharma.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion